Therapeutics to Prevent and Treat COVID-19
The Centers for Disease Control and Prevention (CDC) recommends that eligible individuals should get all vaccines and booster shots as the best preventive measure available against severe disease, hospitalizations, and death due to COVID-19.
Therapeutics are also available for preventing and treating COVID-19 in specific at-risk populations.
Current CDC recommendations for vaccines and booster shots are expected to protect against severe illness, hospitalizations, and deaths from infection with the Omicron variant.
Some studies have found lower effectiveness of the primary series of vaccines against infection and demonstrated the importance of booster doses.
The Omicron variant, with its numerous mutations in the spike protein, is not neutralized by bamlanivimab and etesevimab or casirivimab and imdevimabexternal the most frequently prescribed monoclonal antibody-based COVID-19 treatments.
Sotrovimabexternal icon remains effective against all variants of concern, including Omicron.
Sotrovimab can be used in these high-risk individuals when Paxlovid is not indicated due to potential severe drug-drug interactions or if Paxlovid is not available.
Remdesivir is a nucleoside analog approved by FDA for the treatment of hospitalized patients with COVID-19.
Three daily intravenous (IV) infusion of remdesivir given within seven days of symptom onset.
This study found that the reduction in hospitalization rates was similar to that achieved by using anti-SARS-CoV-2 monoclonal antibody-based therapy.
Remdesivir is expected to be effective against the Omicron variant based on in vitro data.
Outpatient use of remdesivir requires support of IV infusion centers with appropriate skilled staffing.
Two oral antivirals, Paxlovidexternal icon (ritonavir-boosted nirmatrelvir) and molnupiravirexternal icon, are available under for treating COVID-19 in outpatients with mild to moderate disease.
Each drug is administered twice daily for five days.
Severe outcomes were reduced by 88% for Paxlovidexternal icon compared to 30% for molnupiravir.
Initiating treatment with oral antivirals must begin within five days of symptom onset to maintain product efficacy.
There is a potential for severe drug-drug interactions with ritonavir, a medication used for HIV treatment.
Like Paxlovid, molnupiravir is expected to be active against all circulating variants of concern, including Omicron.
Molnupiravir should only be used when other options are not available, due to its lower efficacy.
Molnupiravir use is not recommended in pregnancy or breast feeding or pediatric patients.because of potential mutagenicity, and potential bone growth toxicity.
EVUSHELD is expected to be effective against the Omicron variant.
EVUSHELD is intended for the highest risk immunocompromised patients who are not expected to have an effective response to vaccination.
EVUSHELD is indicated for pre-exposure prophylaxis only and not for treatment of patients with COVID-19.
If the Delta variant still represents a significant proportion of infections in a region and other options are not eligible patients can be offered bamlanivimab and etesevimabexternal icon or casirivimab and imdevimabexternal icon, with the understanding that these treatments would be ineffective against the Omicron variant.
COVID-19 management involves multiple approaches depending on the context – whether you’re referring to public health management, clinical treatment, or personal prevention strategies. Here’s an overview:
Treatment approaches include:
Supportive care for mild cases-rest, hydration, symptom management
Antiviral medications like Paxlovid for high-risk patients when started early
Monoclonal antibodies** in certain situations
Corticosteroids for severe cases requiring hospitalization
Oxygen therapy and mechanical ventilationfor severe respiratory complications Prevention Strategies
Individual prevention measures include vaccination, mask-wearing in high-risk settings, hand hygiene, maintaining distance in crowded spaces, and staying home when symptomatic.
Multiple COVID-19 vaccines have been developed and deployed globally, with updated formulations released periodically to address new variants.
Among individuals with COVID-19 in pregnancy, COVID-19 vaccination was associated with a lower risk of maternal hospitalization and critical care unit admission, as well as pre-term birth.